Seaport Therapeutics Reports Second Quarter 2026 Results, Highlights Positive Clinical Progress and Strengthened Financial Position Following IPO
Seaport Therapeutics, Inc., a clinical-stage biotechnology company focused on developing innovative treatments for neuropsychiatric disorders, has announced its financial results for the second quarter ended June 30, 2026, while providing an update on the continued advancement of its clinical pipeline. The company reported significant progress across multiple development programs, highlighted by encouraging Phase 1 data for GlyphAgo, continued enrollment in its pivotal Phase 2b study of GlyphAllo, and the successful completion of its initial public offering (IPO), which substantially strengthened its financial position.
Together, these achievements position Seaport to advance several important clinical milestones over the next few years as it seeks to develop differentiated therapies for patients living with depression, anxiety, sleep disorders, and other neuropsychiatric conditions.
Strong Quarter Marked by Clinical and Corporate Milestones
According to Seaport’s leadership, the second quarter represented an important period of execution for the company.
Daphne Zohar, Co-Founder and Chief Executive Officer of Seaport Therapeutics, said the company achieved two transformational milestones during the quarter. The first was the release of positive proof-of-concept data from the Phase 1 clinical program evaluating GlyphAgo, while the second was the successful completion of Seaport’s public market debut through its initial public offering.
She noted that the Phase 1 results substantially reduced development risk for the GlyphAgo program and support the company’s plans to begin Phase 2 development for generalized anxiety disorder (GAD) later this year.
Zohar also highlighted continued progress for the company’s lead clinical candidate, GlyphAllo, with both its ongoing Phase 2b efficacy trial in major depressive disorder and a Phase 1 driving simulation study remaining on schedule.
Beyond these programs, Seaport continues to invest in its earlier-stage pipeline, including Glyph2BLSD, a novel non-hallucinogenic neuroplastogen designed to capture the therapeutic mechanisms of psychedelic medicines without producing hallucinations or requiring supervised administration.
With more than $427 million in cash and investments following its IPO, the company believes it is well financed to support multiple clinical readouts expected through 2029.
GlyphAllo Advances Toward Late-Stage Development
GlyphAllo (SPT-300), also known as Glyph Allopregnanolone, remains Seaport’s most advanced clinical candidate.
The investigational therapy is being developed for patients suffering from major depressive disorder (MDD), including individuals with or without anxious distress.
Enrollment Continues in Global Phase 2b BUOY-1 Trial
Seaport reported that enrollment continues as planned in the BUOY-1 study.
The trial is a randomized, double-blind, placebo-controlled global Phase 2b clinical study designed to evaluate both the efficacy and safety of GlyphAllo in adults diagnosed with major depressive disorder.
Importantly, BUOY-1 has been designed as a potentially registration-enabling study, meaning positive results could support future regulatory discussions regarding pivotal development.
The company expects topline data from the study during the first half of 2027.
Driving Simulation Trial Progressing
Alongside BUOY-1, Seaport is conducting a dedicated Phase 1 driving simulation study in healthy volunteers.
This randomized, placebo-controlled trial is intended to evaluate whether evening administration of GlyphAllo affects driving performance the following morning.
Participants receive multiple dose levels of the investigational medicine before undergoing simulated driving assessments approximately nine hours later, reflecting standard approaches used to evaluate medications that may influence alertness.
The study is particularly important because many existing treatments for depression or anxiety may impair cognitive performance or driving ability.
Topline results are expected during the second half of 2026, several months before the anticipated Phase 2b efficacy data.
Clinical Data Presented at ASCP
During May 2026, Seaport presented both oral and poster presentations at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting.
The presentations summarized previously generated Phase 1 and Phase 2a clinical data supporting GlyphAllo while also outlining the design and scientific rationale behind the ongoing BUOY-1 trial.
The company believes these presentations further strengthened awareness of the program within the psychiatric research community.
Positive Phase 1 Results Strengthen GlyphAgo Program
Another major achievement during the quarter involved GlyphAgo (SPT-320), the company’s investigational formulation of agomelatine designed for patients with generalized anxiety disorder (GAD).
Head-to-Head Study Demonstrates Improved Drug Exposure
In April 2026, Seaport announced positive proof-of-concept data from the crossover and single ascending dose portions of its Phase 1 study.
Compared with conventional agomelatine, GlyphAgo achieved:
- A 6.8-fold increase in bioavailability
- A statistically significant improvement over the company’s predefined two-fold target
- Approximately 10-fold lower pharmacokinetic variability
Improved bioavailability may allow therapeutic drug exposure while reducing liver exposure, addressing one of the primary safety limitations associated with conventional agomelatine therapy.
Multiple Ascending Dose Results
Additional positive findings were reported in June from the study’s multiple ascending dose component.
Seven consecutive days of treatment produced therapeutic agomelatine exposure while remaining within dose ranges projected to minimize liver toxicity.
Historically, routine liver function monitoring has limited widespread clinical use of agomelatine in several regions.
Seaport believes GlyphAgo’s improved pharmacologic profile may reduce or potentially eliminate this requirement if confirmed in future studies.
Favorable Safety Profile
Across all study portions, GlyphAgo demonstrated encouraging tolerability.
The company reported:
- No serious adverse events
- No severe adverse events
- No liver-related adverse events
- No clinically meaningful changes in liver function biomarkers including ALT, AST, or bilirubin
These findings provided confidence to advance the program into Phase 2 development.
Phase 2 Development Plans for GlyphAgo
Following completion of the successful Phase 1 program, Seaport outlined two parallel Phase 2 studies.
Phase 2a Proof-of-Pharmacology Trial
The company plans to begin a randomized, double-blind Phase 2a study during the second half of 2026.
This trial will evaluate two dose levels of GlyphAgo in patients with generalized anxiety disorder accompanied by sleep disturbances.
Researchers will examine objective sleep architecture measurements alongside clinical assessments to better understand the drug’s pharmacologic effects.
Topline results are anticipated in early 2028.
Phase 2b Registration-Enabling Trial
A larger Phase 2b study is expected to begin during the first half of 2027.
This placebo-controlled trial will evaluate GlyphAgo’s safety and efficacy in generalized anxiety disorder and has been designed as a potentially registration-enabling study.
Topline data are expected before the end of 2028.
Advancing a Novel Non-Hallucinogenic Neuroplastogen
Seaport also continues development of Glyph2BLSD (SPT-348).
Unlike traditional psychedelic compounds, Glyph2BLSD has been engineered to preserve potentially beneficial neuroplasticity-related pharmacology while avoiding hallucinations or the subjective “trip” commonly associated with psychedelic therapies.
The investigational therapy is being explored for neuropsychiatric disorders as well as headache conditions with substantial unmet medical need.
Because it is designed to avoid hallucinogenic effects, the therapy could potentially eliminate the need for prolonged clinical supervision during treatment, improving accessibility if ultimately approved.
Completion of first-in-human enabling studies remains on track by the end of 2027.
Successful Initial Public Offering Strengthens Balance Sheet
A major corporate achievement during the quarter was Seaport’s successful IPO.
Completed in May 2026, the offering generated $260 million in gross proceeds before underwriting fees and expenses.
Combined with existing financial resources, the proceeds significantly strengthened the company’s balance sheet.
Management expects current cash resources to fund planned operations through 2029, providing sufficient capital to support multiple major clinical milestones across both GlyphAllo and GlyphAgo.
Board Strengthened with Industry Veteran
Earlier this year, Seaport appointed Sharon Mates, Ph.D., to its Board of Directors.
Dr. Mates previously co-founded Intra-Cellular Therapies and served as Chairman and Chief Executive Officer until the company was acquired by Johnson & Johnson in a transaction valued at $14.6 billion.
Her experience leading successful biotechnology companies is expected to support Seaport’s continued growth as it advances toward later-stage development.
Second Quarter Financial Results
Cash Position
As of June 30, 2026, Seaport reported:
- Cash, cash equivalents and investments: $427.3 million
Management believes this capital will fund current operating plans through at least 2029.
Research and Development Expenses
Research and development expenses totaled $24.6 million during the second quarter of 2026, compared with $13.4 million during the same period in 2025.
The increase primarily reflected:
- Advancement of GlyphAllo into later-stage clinical testing
- Continued development of GlyphAgo
- Higher clinical trial expenses
General and Administrative Expenses
General and administrative expenses increased substantially to $41.2 million, compared with $5.1 million during the prior-year quarter.
According to the company, the increase primarily resulted from:
- One-time non-cash stock-based compensation associated with the IPO
- Equity awards granted under the company’s 2024 and 2026 incentive plans
Seaport reported a net loss of $62.6 million for the second quarter of 2026, compared with $15.1 million during the same period last year.
Management noted that the increase was largely attributable to one-time IPO-related stock-based compensation expenses rather than deterioration in underlying operating performance.
Seaport Therapeutics enters the second half of 2026 with momentum across both its clinical pipeline and corporate strategy. The company expects several important milestones over the coming months, including topline data from the Phase 1 driving simulation study of GlyphAllo, initiation of the Phase 2a GlyphAgo trial in generalized anxiety disorder, and continued enrollment in the potentially registration-enabling BUOY-1 Phase 2b study.
Supported by a strengthened balance sheet following its successful IPO and a cash runway extending into 2029, Seaport believes it is well positioned to advance multiple innovative neuropsychiatric programs. As the company progresses toward several pivotal clinical readouts, it aims to develop differentiated therapies that address significant unmet needs for millions of patients living with major depressive disorder, generalized anxiety disorder, and other challenging neurological and psychiatric conditions.
About Seaport Therapeutics
Seaport Therapeutics (Nasdaq: SPTX) is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. Through its differentiated approach, the Company identifies clinically validated mechanisms with established efficacy and safety which had historically been limited by high first-pass metabolism, low bioavailability, and/or side effects. Seaport applies its proprietary Glyph™ platform to overcome those limitations and invent innovative oral therapies. With an experienced team of industry leaders, Seaport has a proven track record in neuropsychiatry drug discovery and development and delivering successful business outcomes. Seaport aims to develop novel, leading treatment options that will make a significant impact for patients and their families.